Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S.

Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S.

BBIST:MEDTR
17.70
TRY
-1.08
(-5.75%)
0.16EPS
195.55P/E
2.64BMarket Cap
Nov 05Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.68
1.95
3.02
3.16
13.41
17.62
23.04
24.15
23.85
Basic EPS, GAAP
0.1
0.11
0.51
1.41
0.96
0.31
0.81
-0.08
0.14
Free Cash Flow per Basic Share
0.62
0.17
0.44
0.23
-0.38
4.21
4.35
2.05
2.69
Dividend per Share
- -
- -
- -
- -
1.18
1.26
0.38
0.32
0.22
Book Value per Share
0.46
0.56
1.82
4.78
12.66
18.09
24.53
24.42
35.96
Tangible Book Value per Share
0.45
0.56
1.82
4.78
12.64
18.07
24.42
23.75
35.01
Basic Weighted Avg Shares
119
119
119
119
119
119
119
119
119
Sales/Revenue/Turnover
199
232
359
376
1,596
2,097
2,741
2,874
2,838
Operating Margin (%)
20.17
14.38
28.37
23.95
24.7
18.35
11.74
4
2.76
Depreciation Expense
9
9
12
12
50
76
116
176
184
Net Income, GAAP
12
13
60
168
114
37
96
-9
17
Effective Tax Rate (%)
6.84
15.4
7.15
17.02
41.67
53.39
3.14
- -
- -
Profit Margin (%)
6.26
5.49
16.82
44.61
7.17
1.78
3.51
-0.32
0.61
Working Capital
93
93
154
491
967
1,149
1,432
1,280
1,462
LT Debt
30
14
26
7
61
65
26
14
7
Total Equity
108
126
217
569
1,509
2,136
2,925
2,929
3,388
Return on Invested Capital (%)
- -
19
41.76
15.22
20.25
9.5
11.1
- -
- -
Return on Capital (%)
- -
2.56
31.69
41.47
12.54
3.77
7.38
- -
- -
Return on Common Equity (%)
- -
20.9
42.51
42.64
11.02
2.05
3.81
-0.32
0.58

Capital Structure

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
25
22
21
LT Borrowings
11
2
- -
LT Finance Leases
2
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
119
95
93
Market Capitalization
3,422
2,573
2,638

Working Capital

TRY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,821
1,900
1,992
Cash, Cash Equivalents & STI
386
480
484
Accounts Receivable, Net
761
709
707
Inventories
550
579
665
Total Current Liabilities
542
531
530
Payables & Accruals
- -
- -
- -
ST Debt
25
22
21
Deferred Revenue
- -
- -
- -

Growth Rates

TRY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
81.17%
0.14%
Free Cash Flow
- -
-315.87%
-52.88%
Net Income, GAAP
- -
25.22%
-109.65%
Sales/Revenue/Turnover
- -
79.21%
4.83%
Total Cash Common Dividend
- -
- -
-16.64%

Quarterly Revenue

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
601
500
737
624
2,741
2025
786
818
648
875
2,874
2026
646
668
- -
- -
- -

Quarterly Earnings Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.31
0.21
0.11
0.81
2025
-0.77
-0.22
0.22
0.55
-0.08
2026
-0.46
-0.16
- -
- -
- -

Quarterly Dividends Per Share

TRY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.38
2025
- -
- -
- -
0.22
0.32
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
796
Sector
Health technology
Industry
Medical specialties
Address
Karabaglar Turkey
IPO Date
Jul 2, 2021
Business
Meditera Tibbi Malzeme Sanayi Ve Ticaret A.S. is a Turkey-based medical device manufacturer and distributor specializing in the design, development, and production of single-use medical consumables, respiratory care systems, and hazardous drug preparation technologies. Founded in 1983 and headquartered in Izmir, Turkey, the company operates in the medical technology and healthcare supplies sector, serving public and private hospitals, healthcare institutions, and distributors worldwide. Meditera offers a comprehensive portfolio organized into key product categories, including respiratory and anesthesia products, such as anesthesia breathing circuits, mechanical ventilator sets, heat and moisture exchanger (HME) filters, bacterial and viral breathing filters, catheter mounts, manual resuscitators, and oxygen therapy masks; infusion therapy and vascular access solutions, such as gravity infusion sets, IV extension lines, stopcocks, needleless connectors, blood transfusion sets, and specialized closed system drug transfer devices (CSTD) for the safe compounding and administration of hazardous cytotoxic oncology drugs; surgical drainage and suction devices, such as surgical suction connecting tubes, yankauer handles, and wound drainage systems; and blood collection and laboratory consumables, including vacuum blood collection tubes and in-vitro diagnostic products manufactured through affiliated entities such as Altech and Disera. The company also provides contract manufacturing services, including original equipment manufacturer (OEM) and original design manufacturer (ODM) solutions for global medical brands. Meditera operates specialized manufacturing and cleanroom facilities in the Tire Organized Industrial Zone in Izmir, distributing domestically and exporting to more than 80 countries across Europe, the Middle East, Asia, and the Americas. In recent developments, the company has completed major cleanroom and manufacturing automation expansions at its Izmir production campus to scale output for high-margin closed system drug transfer devices and respiratory circuits; advanced its product portfolio through the European Union Medical Device Regulation (MDR) certification process; expanded international commercial distribution networks and OEM partnership agreements with multinational healthcare corporations across Europe; and introduced next-generation oncology drug preparation and delivery product variants to strengthen healthcare personnel safety protocols against hazardous chemical exposure.